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ABSTRACT 
 
Introduction: Autologous peripheral blood hematopoietic progenitor cell collection (A-
HPCC) in pediatric patients is considered relatively safe although technically 
challenging. Very little is known regarding the incidence, risk factors and impact of 
procedure-related adverse events (AE) on pediatric A-HPCC outcomes. 
Methods: Prospective 4.5 year review of AE associated with pediatric A-HPCC. AE 
were graded by severity and type. Potential demographic and procedural risk factors, and 
the impact on product quality, were compared by t-test, chi-square, and linear regression.  
Results: Sixty-two children underwent 110 A-HPCC, including 36 (58%) under 20 kg. 
Fifty-five AE were documented in 25.4% A-HPCCs and 39% of children (citrate 25%, 
access 19%, technical 11%, cardiovascular 0%, allergic 1.8%). No AE were noted in 
children < 10 kg anticoagulated with heparin. Access and technical AE accounted for 
73% of severe AE, with line-related problems underlying most technical AE (87.5%, 
p=0.006). AE were more likely in older (p=0.012), heavier patients (p=0.02), who 
frequently required more than one A-HPCC (p=0.012). In contrast, young children were 
more likely to experience citrate AE with gastrointestinal symptoms (median age, 6 
years; p=0.076). AE had no impact on CD34 collection rates; however, mean CD34 
yields (4.2 vs 20.4 million/kg; p=0.0035) were decreased in patients with technical AE 
due to lower peripheral CD34 counts and a high number of aborted procedures (37.%).   
Conclusion: Venous access and flow-related issues are a major factor associated with 
moderate and severe AE, effecting approximately 10% of patients. AE are more frequent 
with increasing patient age, weight and number of procedures.
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Introduction 
Peripheral blood hematopoietic progenitor cell collection (HPCC) is considered a 
relatively safe procedure both in adults and pediatric patients. Young pediatric patients, 
however, can present unique challenges due to their size and small blood volume, which 
may increase their risk of adverse events (AE).  The latter includes hypotension and 
hemodynamic instability due to fluid shifts, citrate anticoagulation, dilutional and 
iatrogenic anemia [1-5]. Adequate venous access is another challenge with all the 
attendant risks associated with central venous catheters (CVC) [1-3]. Finally, the need for 
a blood prime and slow inlet rates required for A-HPCC in very small children can lead 
to delays in establishing and maintaining a stable interface [2], increasing both total 
volume processed and procedure times [6].  
Large studies on procedural AE in pediatric apheresis are relatively scarce [3,7]. 
Pediatric bone marrow registry studies have predominantly focused on pediatric 
allogeneic HPC donations, with reported AE commonly restricted to procedural cell 
losses, G-CSF toxicity, and catheter-related complications [8-11]. AE data associated 
with pediatric autologous collection (A-HPCC) is more limited, with many studies more 
than 20 years old. Nearly all published reports are small retrospective, single-institution 
studies with less than 40 patients, varying anticoagulation and priming protocols, and 
may include both auto- and allo-donors [2-4,12-20] In addition, reported data seldom 
includes AE due to technical issues during the procedure.  
In April 2009, our institution began prospectively documenting AE associated 
with A-HPCC in both adult and pediatric patients. We now report our results and analysis 
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of procedure-related AE in 62 pediatric patients and 110 A-HPCC procedures over a 4.5 
year period. This is the largest, and only the second, prospective study of procedure-
related AE associated with pediatric A-HPCC [17]. It is also one of the largest reported 
studies in children < 20 kg undergoing large volume leukapheresis (LVL).  
 
MATERIALS AND METHODS: 
Documentation and Prospective Collection of Adverse Events:  
In April 2009, the University of Michigan redesigned the HPC collection procedure 
flowsheet that included a dedicated mandatory field for documentation of observed AE. 
AE were defined as: 1) growth factor (granulocyte colony-stimulating factor; G-CSF), 2) 
anticoagulation, 3) venous access, 4) technical and 5) “other”. AE were also graded as 
mild, moderate or severe (Table 1). Any event graded as moderate or severe required a 
written descriptor in a free text field. Flowsheets were reviewed daily by peer staff 
members for completion and accuracy. An audit was performed 9 months after 
implementation of the new form for compliance and consistency in grading [21]. 
Procedure-related data for each collection, including AE, were recorded by the Cell 
Therapy Laboratory staff as part of the department’s internal quality assurance program. 
All AE, treatment and clinical outcomes were also included in the daily medical 
procedure note by the apheresis attending physician. 
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Patients and Study Design: 
The study was a 4.5 year retrospective review of prospectively-collected, procedure-
related AE during HPCC at the University of Michigan between 4/2009 and 12/2013.  
Inclusion criteria included an age < 18 years of age at time of A-HPCC. Only AE 
attributed to citrate anticoagulation, venous access, technical issues and “other” were 
studied. Only 3 children (ages 9-16) had documented AE due to G-CSF, defined as 
symptoms and complaints present prior to A-HPCC procedure.  AE due to G-CSF were 
excluded from further analysis due to the small number of documented AE available and 
potential underreporting in very young children, which depended on second-hand 
observations by parents.   
Primary data elements included AE type, AE description, and any medical 
intervention required. Procedure-related information included type of venous access, 
anticoagulation regimen, blood prime, volume processed, inlet flow rates, procedure time 
and product characteristics. Patient demographic and laboratory information included 
age, sex, weight, medications, total blood volume (TBV), primary diagnosis, mobilization 
regimen, and pre-procedure blood counts (CBC, CD34, WBC differential). 
 As a comparison group, AE were also examined in 82 adult multiple myeloma 
patients who underwent 210 A-HPCC during the 2013 calendar year. Adult myeloma 
patients were collected for a target of 6 million CD34/kg. In adults, data was limited to 
AE type and venous access.  
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Venous Access 
Most patients underwent short-term, double lumen CVC placement the morning of their 
first A-HPCC. Line care was per institutional guidelines [22]. Following each apheresis 
session, the catheter ports were flushed initially with 5 mL saline, followed by heparin 
(1:1000 units/mL, 0.9-1.3 mL fill volume) and then capped. Femoral and other non-
tunneled catheters were removed within 24 hours of the last A-HPCC.  
 
HPC Collection 
All patients underwent LVL by continuous-flow centrifugation (COBE Spectra, Gambro 
BCT, Lakewood, CO) using the WBC collection set [23]. A total of 3 TBV were 
processed per procedure [23-25]. MNCs were collected at a blood plasma interface of 1% 
to 2% hematocrit, a mean inlet volume of 1 mL/kg/min, and a collection volume of 1.0 
mL/min. For patients weighing less than 10 kg body weight, A-HPCC was performed in 
the pediatric intensive care unit, using a reconstituted whole blood prime and systemic 
heparin anticoagulation (30 units/kg) [24].  Heparin was monitored by the activated 
clotting time (therapeutic range, 180-220 sec). To prevent clotting of the product, ACD-A 
was manually added to the final product (10% final product volume). 
Patients weighing more than 10 kg were anticoagulated with ACD-A at an 
anticoagulant: whole blood (AC:WB) ratio of 1:12.  To mitigate against dilutional anemia 
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and hypotension, a RBC prime was used if the extracorporeal volume was greater than 
10% of the patient’s total blood volume. Patients received prophylactic calcium gluconate 
(3%, 22.6 mg/mL in 100 mL normal saline) on a weight-based scale range to prevent 
citrate toxicity [24], where flow rate range = [(patient weight in kg] x (30 to 90 mg/mL)] 
÷ 22.6 mg/mL calcium gluconate solution ÷ 3 hours (approximate total infusion time).  
RBC for machine priming were ABO/Rh compatible, pre-storage leukoreduced, and 
irradiated. Patients who required a blood prime were premedicated with antihistamine 
and acetaminophen [24]. To avoid volume overload, no rinse-back was performed at the 
end of the procedure. 
 
Product Analysis 
Product volume, WBC count, WBC differential and CD34 count were determined on all 
collected units. Cell counts and WBC differential were performed on the Sysmex XE 
5000 (Sysmex, Kobe, Japan). CD34 yields were determined by flow cytometry 
(Gallios
TM
; Beckman-Coulter, Brea, CA) as recommended by the International Society of 
Hematology and Graft Engineering (ISHAGE) [25,26]. Sterility testing of each product 
was performed before and after processing using the USP culture method per 21 CFR 
610.12 [23,24,27]. All cell processing was performed in biosafety hoods, located within a 
certified clean room. Cells were volume adjusted and frozen in 10% dimethyl sulfoxide 
as described previously [23-25].  
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Data Analysis 
Quantitative data were reported as the mean ± standard deviation (SD) unless noted 
otherwise. Variables with wide inter-patient values were reported as mean, median and 
range. CD34 and MNC collection efficiencies (CE) were calculated as described by 
previously [23,28]. Categorical data were analyzed by chi-square and odds ratio (OR) 
using EpiInfo
TM
 (Centers for Disease Control and Prevention, Atlanta, GA). Linear 
regression, graphics and t-test were performed with commercial software (Kaleidograph, 
Synergy Software, Reading, PA). A p value < 0.05 was considered significant.  
 
RESULTS 
Patient Demographics 
Sixty-two pediatric patients underwent 110 procedures over a 4.5 year period (Table 2). 
Nearly all patients were collected during recovery from treatment-related chemotherapy 
(60/62, 97%). Patients ranged in age from 1 to 18 years of age, with a median age of 4.5 
years. Forty-three percent of children were less than 3 years of age and 56% weighed less 
than 20 kg.  Sixty-one percent of patients required a blood prime. No patient was on an 
ACE (angiotensin converting enzyme) inhibitor at the time of A-HPCC. 
The majority (72%) of subjects had a diagnosis of neuroblastoma or central 
nervous system tumors, and accounted for the predominance of very young children in 
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our study cohort. Per treatment-specific protocols, these patients were collected for a final 
target yield of 10-15 million CD34/kg to support three consecutive stem cell rescues 
following myelo-ablative chemotherapy (Table 2) [24]. The remaining children carried a 
diagnosis of lymphoma (Hodgkin’s lymphoma, n=8; B cell lymphoma, n=2), 
hepatoblastoma (n=1), germ cell tumor (n=1), Ewing’s sarcoma (n=2) and carcinoma 
(n=3).  In general, these children were older (median 14 years, p<0.0001) and were 
collected following chemotherapy for a single transplant of 3-5 million CD34/kg. 
Overall, 61% of patients collected in a single procedure. 
 
AE in pediatric A-HPCC 
A total of 55 individual AE were documented in 24 (38.7%) children and 27 procedures 
(24.5%) (Table 3). The majority of AE were graded as moderate (54.5%) or severe 
(27.3%).  Most severe AE (73%) were technical and venous access.  
Patients requiring more than one procedure were more likely to experience at least 
one AE over the course of treatment (58% vs 27%, p=0.012).  In general, AE tended to 
be more common in older and larger children, who were also more likely to require 
several procedures (Fig. 1, p=0.07). When examined by diagnosis, AE were also higher 
in children with “other” diagnoses (71% vs 29%, p=0.008), most of whom were older 
(9.5 ± 4.4 yrs). In contrast, no AE were observed in 6 children < 10 kg, who were 
systemically anticoagulated with heparin and required only a single procedure.  
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AE due to citrate anticoagulant 
Side effects due to citrate anticoagulant were noted in 25% of patients (14/56) and 14% 
(15/106) of procedures (Table 4). Severe AE (5.4% patients) were limited to 
gastrointestinal symptoms: no hypotension or tetany were noted. Gastrointestinal 
symptoms composed the majority of AE (75%, 9/14) and included abdominal pain, 
nausea, vomiting and diarrhea.  Neurologic symptoms were recorded in 7 (12%) patients 
and included parasthesias, lightheadedness and agitation. Agitation occurred in one child 
in three successive collections within 30 minutes of starting cell collection. Neurologic 
symptoms, including agitation, were mild and responsive to increasing the calcium 
replacement infusion rate.  
The incidence of citrate AE increased over time (Fig. 2C), with citrate AE 
accounting for 100% of all AE documented after the first 2 days. Likewise, there was an 
increase in citrate AE in heavier children, who were more likely to require several 
procedures (Fig. 2B). Like adults [29,30], citrate AE tended to be more common in 
females although the difference did not reach clinical significance (30% vs 15.6% males, 
p=0.18). There was no correlation between citrate AE by patient diagnosis (p=0.19-0.47). 
Young and small children were more likely to experience gastrointestinal symptoms 
(median age 6 years; median weight 24 kg) whereas neurologic symptoms were more 
common in older children (median age 11.8 years, p=0.076) (Fig. 2A). Ten procedures in 
8 patients were associated with a specific nurse operator. 
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Because all patients responded to medical management, no intra-procedure 
electrolytes were drawn. A review of pre- and 24 hour post-procedure electrolytes 
showed a mildly decreased total calcium in one patient (8.0 mg/dL). 
 
AE due to Venous Access 
Ninety-two percent of patients had a CVC for venous access on day 1 (Table 3), 
including all patients under 11 years of age. A short-term femoral dialysis catheter was 
the predominant catheter in 76% of patients.  Five older patients (12-18 years) were 
originally scheduled for A-HPCC using peripheral IV access (PIV).  
 A total of 18 venous AE were documented in 13 procedures (12%) and 19% 
(12/62) of patients (Table 4). Six patients had more than one documented AE per 
procedure.  Six AE were mild (33%), 7 were moderate (39%) and 5 severe (28%). 
Venous AE included bleeding, pain; occluded CVC requiring multiple flushes throughout 
the procedure, reversal of arterial and venous lines, PIV for draw, or positional 
maneuvers; multiple venipunctures, and  procedure cancelled or terminated early due to 
access issues. In 47 patients with femoral lines, approximately 15% had at least one line-
associated AE.  Patients with internal jugular and subclavian CVC had a line-associated 
AE rate of 50% (p= 0.013).There were no instances of infection, thrombosis or 
arteriovenous fistula associated with femoral CVC. One patient developed a small 
hematoma following CVC removal. 
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Five procedures in four patients were associated with PIV and multiple 
venipunctures. All four patients were considerably older (16.8 ± 1.2 years) and larger (70 
±  20 kg, range 57-103). In one patient, the procedure was cancelled pending emergent 
CVC placement. One patient lost a PIV midway through the procedure and required 
several attempts to re-establish venous access.  Two patients with poorly functioning 
CVCs required placement of a PIV for draw (n=1) or return (n=1). 
 Like pediatric allogenic donors [10], bleeding and pain were usually associated 
with newly placed CVC and tended to occur in younger patients (median 5.5 years).  
Bleeding was minimal and limited to oozing around the insertion site and responded to 
pressure (n=1) or a topical clotting agent (n=1). No patient required a blood transfusion 
for catheter-related blood loss. Mild pain was treated with acetominophen in two patients: 
one patient required morphine for pain relief.  
 
Technical AE 
Twenty-two moderate to severe technical AE were documented in 7 patients (11%) and 9 
procedures (8%).  AE included slow inlet rates, multiple alarms, an unstable interface, 
prolonged procedure times, clotted circuit with blood loss and premature termination of 
the procedure (Table 4, Supplemental Data, Table S1). Most AE (8/9) were due to poorly 
functioning CVCs. In patients with newly placed femoral lines, catheter-related issues 
were encountered after day 1.  In one older patient, poor CVC function was attributed to 
placement of a left subclavian CVC that was too small for her age and size.  
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Prolonged procedure times occurred in 66% (6/9) of affected procedures.  In four 
procedures, inlet rates were less than 1 ml/kg/min (range, 0.31-0.72; Table S1). In one 
patient, prolonged procedure times were due to a long delay in establishing the interface 
following a RBC prime [6].  In general, technical AE increased procedure time by 35 
minutes (range 8-105 minutes) relative to case-matched controls (TBV ± 5%). Due to 
slow inlet rates, three procedures did not achieve a full LVL collection. Prolonged 
procedure times may have contributed to citrate AE in two patients. 
 
Other AE 
One patient had a mild allergic reaction to the RBC prime. Symptoms were limited to 
pruritis and rash and responded to additional antihistamines. No patient had hypotension 
or hemodynamic instability.  
 
Comparison of AE in pediatrics and adults 
Pediatric allogeneic donors are reported to have less AE than adults due, in large part, to 
significantly less G-CSF toxicity [10]. To determine whether the same was true for A-
HPCC, we compared procedure-related AE in pediatric patients to 82 adult myeloma 
patients who underwent a total of 210 A-HPCC during the 2013 calendar year. Overall, 
AE were slightly more frequent in adult patients (48% vs 39%) although the AE rate per 
procedure was identical (~25%, Table 4). There was no significant difference in citrate-
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related AE between children and adults. Children, however, were three times more likely 
to experience gastrointestinal symptoms (16% vs 9%, OR=3.38) whereas parasthesias 
were common in adults (31% vs 9%, p=0.002).  Children were also more likely to have 
technical problems due to CVC-related issues (85.7%, p=0.006; OR=27). Unlike 
pediatric patients, most adult patients were collected using PIV (75.6%, p<0.00001).   
Most alarms in adults were attributed to slow inlet flow, high return pressures or machine 
obstructions/malfunctions associated with a new blood separator. 
 
Impact of AE on cell collection 
We also examined the impact of AE on CD34 collection and HPC product quality. 
Technical AE due to flow problems have the potential to interfere with a stable interface. 
Furthermore, reversal of arterial and venous lines using dual lumen catheters is reported 
to increase recirculation by 7% to 20%, with decreases in CD34-CE [17,31,32].  Finally, 
multiple venipunctures, repeated line flushing and manipulation could increase the risk 
for bacterial contamination. 
 AE had no impact on the CD34 collection rate per peripheral CD34 count: the rate 
of collection was similar, regardless of the presence or type of AE (Fig 3A-D). There was 
also no significant difference in MNC-CE (range, 47-56%) or CD34-CE (54-57%) by AE 
(Supplemental Data, Table S2). There was also no difference in the mean CD34 and 
MNC yields. When examined by specific type of AE, products associated with technical 
AE tended to have lower CD34 yields (4.2 vs 21.6 million/kg, p=0.00035) due to lower 
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peripheral CD34 counts and a high number of aborted procedures (3/8, 37%). There were 
no positive cultures with any product collected.  
 
DISCUSSION 
Children are often perceived to tolerate HPCC better than adults, with significantly less 
G-CSF toxicity [10]. In adults, procedure-associated AE average 9-13% per procedure 
and 12 to 42% per patient, with higher rates observed in women and low body weights 
[7,29,30]. In healthy pediatric donors, procedural AE rates range from 20-40% per patient 
[10,11], which is compatible with our results (39%).  
 Young age, small size and an increasing number of procedures are all reported AE 
risk factors in pediatric apheresis [3,4,11]. In pediatric HPCC, Sevilla et al have reported 
an inverse relationship between patient size and AE rates, with the highest rates in 
children < 10 kg (>90%), falling to 51% in children < 20 kg and 20% in children > 20 kg 
[4,11]. In contrast, we found that older and heavier children had the highest AE rates, 
reaching 56% in children > 40 kg (Fig 1). Older children were also more likely to have 
more procedures, increasing the likelihood for procedure-associated AE (Table 3).  
Michon also noted a correlation between AE rates and number of apheresis procedures, 
with 82% of children eventually experiencing at least one AE during the course of 
treatment [3]. 
 Citrate was the most common AE encountered, with at least one citrate AE 
observed in 25% of children. This is consistent with prior pediatric (7-25%, Table 5) and 
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adult studies [2,3,8,10,13,14,16, 29, 30, 33]. In our study, the risk of citrate AE was 
higher in older and heavier patients, who often required several procedures (Fig 2). We 
did not observe citrate or other AE in children < 10 kg, who were systemically 
anticoagulated with heparin. A marked reduction in citrate AE is also reported using low 
dose-citrate and heparin anticoagulant regimens (10 units/mL heparin in ACD-A), 
although citrate-associated hypotension and hypocalcemia can still occur in ~ 5% of 
patients [2,17,20,33,34].  Other cited advantages of heparin-based anticoagulation are 
decreases in net fluid balance, hypokalemia and base excess and an increase in blood 
volume processed per unit time [17,33,34].   Disadvantages of heparin are greater 
procedural platelet losses, prolonged coagulation abnormalities, bleeding and potential 
heparin sensitization. [17,33-35] 
We did not observe any episodes of hypotension, which have been reported in 0.7 
to 90% of pediatric patients (Table 5) [2-4,10-12,14-16]. Very young children are at 
particular risk for procedure-associated hypotension due to small blood volumes, fluid 
shifts, dilutional anemia and iatrogenic blood losses associated with infectious disease 
testing, cell counts and other laboratory tests [5].  Hypotension can occur early in the 
procedure, particularly when using older blood separators with large extracorporeal 
priming volumes [1,2,5,12,14,18]. Hypotension and hemodynamic instability occurring 
late in the procedure is typically attributed to citrate [2] or can follow blood losses arising 
from catastrophic instrument malfunctions [4,5].  
To avoid hypotension, most centers, including our own, perform a blood prime 
whenever the extracorporeal volume exceeds 10-15% of the patient’s blood volume [1-
Page 16 of 39
John Wiley & Sons
Journal of Clinical Apheresis
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
17 
 
5,8-10, 12-15,17-20]. In addition, most centers have policies specifying a minimum pre-
procedure hemoglobin, which can range from 8 to 12 gm/dL [3,16]. Although we did not 
observe hypotension, other studies have still documented episodes of hypotension despite 
a RBC prime (Table 5)-- especially in children anticoagulated with citrate [3,12-15]. It is 
possible this could reflect a combination of endothelial dysfunction and lower 
endogenous ACE levels by G-CSF [36], coupled with a bradykinin release syndrome 
analogous to that described in small pediatric dialysis patients [37,38]. Infants are 
particularly dependent on the renal angiotensin system for blood pressure control and are 
highly sensitive to decreases in ACE activity [39].  Disadvantages of a RBC prime are 
delays in establishing an interface, the potential for transfusion reactions and higher 
procedural platelet losses [6,12,17]   
Some institutions use albumin to prime the circuit, sometimes coupled with higher 
pre-procedure hemoglobin levels [Table 5]. A review of the literature, however, suggests 
that albumin may not be appropriate in all patients. As shown in Table 5, some of highest 
rates of hypotension in children < 20 kg were associated with albumin priming [11,16].  
Sevilla et al reported cardiovascular symptoms in 48% of healthy pediatric donors < 20 
kg undergoing allogeneic HPCC [11]. A similar cardiovascular AE rate was noted by 
Orbach et al associated with A-HPCC in small children [16]. 
Few studies have documented technical AE associated with pediatric A-HPCC.  
We recorded technical AE in 7 patients (11.3%) and 9 procedures (8%). Unlike adult 
patients, technical AE in pediatric patients were overwhelming CVC-related (85.7%, 
p=0.002), leading to interface delays, prolonged procedures and/or short collections. We 
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observed one severe technical AE due to clotting of the circuit. Technical AE due to 
instrumentation and circuit loss tend to be severe, often leading to aborted procedures, 
blood loss and potentially product loss [2-5,16,30]. Fortunately, instrumentation 
problems are relatively uncommon during HPCC, with reported rates ranging from 0.4-
7% in children and adults [3,14,30]. This is sharp contrast to pediatric dialysis where 
alarms, instrument shutdowns and circuit loss eventually occur in the majority of patients 
[37].   
The rate of technical AE in our study is equivalent to that reported by others. 
Michon et al reported technical AE in 19.7% of all pediatric apheresis procedures, 
including A-HPCC [3]. In pediatric HPCC, technical AE have been reported in up to 24% 
of patients and 12% to 20% of procedures [14-17]. Like our study, most technical AE 
were CVC-related, requiring reversal of lines or “extreme positional maneuvers” to 
complete the procedure [14,17]. In contrast, CVC-related technical AE were significantly 
less common in our adult patients, who are routinely collected by PIV whenever possible. 
In a recent study, alarms due to a slow inlet flow rate occurred in only 0.69% of adult A-
HPCC [30].  
 The high frequency of CVC-related technical AE in our pediatric patients reflects 
the difficulty and importance of establishing adequate venous access in this population 
[1,2]. In one of our patients, the catheter (9 French) was clearly too small for the patient’s 
age and weight (68 kg) [40]. Four of our patients had a left-sided subclavian CVC, with 
line-related AE documented in 2 patients and 3 procedures, and decreased CD34-CE 
(40% vs 58%, p=0.03). Left-sided subclavian CVC have a documented higher rate of 
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malfunction [21,41-43], including HPCC.   In a study of Neostar CVC, 42% of patients 
with left-sided CVCs had at least one AE (p<0.001), including significant procedural 
delays (24%) and aborted procedures (8%) [43]. Likewise, we have reported a 19% 
severe AE rate with left-sided CVC in adult A-HPCC [6]. At our institution, left 
subclavian placement is avoided whenever possible. 
Our practice has favored the placement of a temporary, dual-lumen femoral 
dialysis catheter in young children undergoing A-HPCC. Patients generally undergo line 
placement the morning of their first scheduled collection, followed by LVL in the 
afternoon. Nearly half of our patients collected in a single session and 36% within two 
sessions: Only 6 patients (13%) required a femoral CVC more than 3 days (range, 1-6 
days). Flow-related AE were observed in 15% of patients and 5% of procedures on day 2 
or later. Access and flow-related AE were significantly less common with femoral CVC 
than all other types of venous access (43% AE), especially subclavian and internal 
jugular CVC (50% AE). Femoral CVC also have a relatively low rate of flow-related in 
adult A-HPCC patients, with alarms and occlusion occurring after 2-3 days [44]. Patients 
undergoing A-HPCC may be at higher risk for CVC occlusion, in general, due to G-
CSF’s prothrombotic effects on platelet reactivity and coagulation factors [36,45-49]. 
Prophylactic calcium gluconate infusion through the return line may also increase the risk 
for catheter malfunction [50]. 
Heparin and heparin-citrate anticoagulation might reduce catheter malfunction 
rates since it would avoid or minimize the need for calcium replacement, while increasing 
the blood volume processed per unit time. Studies using heparin-based anticoagulation in 
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small children rarely encounter issues with short-term catheters [4,18]. Likewise, we did 
not observe any catheter-related technical or other AE in 6 patients receiving systemic 
heparin anticoagulation  although all of these patients collected in one day. A 
randomized adult trial comparing ACD-A versus heparin-based anticoagulation found no 
difference in catheter malfunction rates, however, the study limited its analysis to the first 
A-HPCC only [33]. An earlier study by Reik et al reported CVC-related flow problems in 
13% of adult A-HPCC using a 6 U/mL heparin/ACD-A regimen [34]. In pediatric 
dialysis, citrate appears superior to heparin anticoagulation, with significantly fewer 
episodes of clotting, circuit loss and a longer circuit life [37,50]. 
In summary, our study shows an overall AE rate of 39% of patients and 14% of 
procedures. As a single institutional study, inherent weaknesses are the number of 
patients, which are heterogenous relative to age, underlying diagnosis and target CD34 
yields. Despite the latter, this is the largest study limited to autologous pediatric patients, 
and is more homogenous and detailed than most other published studies. Contrary to 
earlier studies, we found that older and heavier children were at greater risk for 
procedure-related AE. Unlike younger patients, older children were more likely to use 
alternate venous access, with an increased incidence of venous and flow-related issues. In 
addition, older and heavier children often required more procedures and more total citrate 
exposure. Possible methods to decrease AE in this population include optimizing CD34 
mobilization and use of citrate-heparin anticoagulation. Active monitoring of venous 
access issues and have led to discontinuation of some brands, early venous access 
assessment in older children by apheresis nursing staff, and avoidance of outside CVC 
placement for HPCC. 
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Abbreviations: ACE, angiotensin converting enzyme; AE, adverse event, CE, collection 
efficiency; CVC, central venous catheter, (A-)HPCC, (autologous) peripheral blood 
human progenitor cell collection; LVL, large volume leukapheresis; PIV, peripheral IV; 
TBV, total blood volume. 
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Table 1: Grading of Procedure-Associated AE 
 
AE Category Mild Moderate Severe 
    
Anticoagulant 
(ACD-A) 
Mild parasthesia resolved by 
increasing calcium infusion rate 
Parasthesia at maximum calcium 
infusion rate  
 
Any of the following: 
Nausea, vomiting, abdominal pain, 
hypotension, tetany 
  Calcium boluses  
  Pause in the procedure  
    
Venous Access One restart of line Restart of lines > 2 times Chronic access issues requiring 
multiple saline flushes 
 Mild bleeding at line site, controlled 
by dressing 
Positional changes Urokinase required 
 Mild pain at catheter site Line reversal Procedure aborted/terminated due 
to access issues 
  Recirculation Hematoma/venous thrombosis 
  Peripheral IV for draw and 
catheter/port for return 
Blood loss requiring transfusion 
  Bleeding requiring pressure  
  Pain requiring narcotics  
    
Technical Occasional alarm Interface instability Machine malfunction 
  Multiple alarms Circuit clotting 
  Slow inlet rate Tubing breach or kinking 
  Prolonged procedure Circuit change required 
   Blood loss in circuit 
   Procedure terminated early 
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Table 2: Patient Demographics 
 
Variable Number Patients 
No. Patients 62 
Sex (M/F) 30/32 
Median Age, years (%) 4.5 (range, 1-18) 
< 3 years 27 (44%) 
> 4 years 35 (56%) 
Median weight (%) 18 (range, 8-103) 
<10 kg 6   (10%) 
10-20 kg 30 (48%) 
20-40 kg 10 (16%) 
40-60 kg 8   (13%) 
> 60 kg 8   (13%) 
Blood Prime 38 (61%) 
Diagnosis (%)  
Neuroblastoma 25 (40%) 
Brain Tumor 20 (32%) 
Lymphoma 10 (16%) 
Hepatoblastoma 1 (1.6%) 
Germ Cell Tumor 1 (1.6%) 
Ewing’s Sarcoma 2 (3.2%) 
Ovarian Cancer 2 (3.2%) 
Testicular Cancer 1 (1.6%) 
Mobilization (%)  
Chemotherapy 60 (97%) 
Growth-factor only 2 (3%) 
Remobilization 0 
Blood Counts Day 1  
WBC (10
9
/L) 24.5 ± 17 (range, 4.6-64.4) 
% MNC 18.3 ± 12.6 (range, 3-56%) 
MNC (10
9
/L) 3.9 ± 4.6 (range, 1-54.2) 
% CD34
a
 1.34 ± 0.23 (range 0.01-7.43%) 
CD34 per uL
a
 211.2 ± 42 (range, 1.1-1957) 
CD34 Target Yields  
3-5 x 10
6
/kg  16 
10-15 x 10
6
/kg 46 
 
a. mean ± SEM.
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Table 3: Comparison of Patients with and without AE 
 
  Adverse Event (AE) 
Variable All Yes No P 
No. Patients (%) 62 
(100%) 
24 
(39%) 
38 
(61%) 
- 
Age, years 
(median) 
6.6 ± 5.5 
( 4.5 ) 
8.8 ± 6.0 
( 8.5 ) 
5.2 ± 2.3 
( 3 ) 
0.012 
M/F 30/32 10/15 20/17 0.28 
Weight, kg 
(median) 
29.1 ± 24 
(18) 
37.7 ± 28 
(27) 
23.7 ± 20 
(16) 
0.02 
TBV, mL 
(median) 
1988 ± 1388 
(1357) 
2600 ± 1581 
(2606) 
1574 ± 1080 
(1150) 
0.005 
Diagnosis (%)     
Neuroblastoma 25 (40%) 7 (28%) 18 (72%) 0.11 
Brain Tumor 20 (32%) 8 (40%) 12 (60%) 0.88 
Lymphoma 10 (16%) 4 (40%) 6 (60%) 0.98 
Other  7  (11%) 5 (71%) 2 (29%) 0.008 
Total No. Procedures 110 52 58 - 
Volume processed (L) 6.86 ± 6.10 7.06 ± 4.8 6.80 ± 6.5 0.85 
Avg. Procedures/Patient 1.8 ± 1.2 2.0 ± 1.1 1.5 ± 1.1 0.14 
Patients > 1 Procedure (%) 24 (39%) 14 (58%) 10 (27%) 0.012 
No. Procedures ≥ 1 AE 110 27 83 - 
No. Proc/AE per day (%AE)     
Day 1 62  13 (21%) 49 ref 
Day 2 24  8 (33%) 16 0.23 
Day 3 14  4 (29%) 10 0.54 
Day 4-6 10  2 (20%) 8 0.95 
Anticoagulation     
Heparin 6 0 6 0.04 
ACD-A 56 24 32 0.04 
RBC prime  38 12  26  0.15 
Venous access     
    PIV 5 3 2 0.32 
    CVC  57 21 36 0.32 
CVC Brand
a
     
medCOMP® 5 1 4 0.41 
Arrow International® 25 6 19 0.08 
Mahurkur
TM
 20 10 10 0.13 
NeoStar
TM
 4 2 2 0.57 
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Powerline® 3 2 1 0.27 
Anatomic Placement     
Femoral 47 16 31 0.35 
Left subclavian 4 2 2 0.57 
Right internal jugular 6 3 3 0.48 
 
a. Double lumen, dialysis CVC included Mahurkar
TM
 (8-12 F, Covidein, Mansfield, 
MA), medCOMP (7 F, Haleysville, PA) and Arrow International (12 Fr, Reading, PA). 
Tunneled CVC included Powerline® (Bard, Tempe, AZ) and NeoStar
TM
 
(Angiodynamics, Latham, NY). 
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 Table 4: Comparison of Procedure-related AE in Pediatric and Adult Patients 
 
 Pediatric Patients 
(n=62) 
Adult Patients 
(n=82) 
AE in Peds vs Adults 
AE Type No. AE
a
 % AE
b
 No. AE % AE P OR (95% CI)
c
 
Heparin Anticoagulant
d
  0/6 0 0/1
e
 0 -  
       
Citrate Anticoagulant
d
  14/56
a
 (25%) 27/81 (33.3%) 0.29  
Gastrointestinal 9 (16.1%) 4 (4.9%) 0.09 OR=3.68 (1.1-12.6) 
Nausea/vomiting 3 (5.3%) 4 (4.9%) 0.91  
Abdominal pain 5 (8.9%) 0 0 0.006  
Diarrhea 1 (1.8%) 0 0 0.23  
Neurologic 7 (12.5%) 26 (32.1%) 0.008 OR=0.30 (0.12-0.76) 
Parasthesia 5 (8.9%) 25 (30.9%) 0.002 OR=0.22 (0.07-0.60) 
Lightheaded 1 (1.8%) 0 0 0.23  
Agitation 1 (1.8%) 0 0 0.23  
Muscle cramping 0 0 2
f
 (2.5%) 0.24  
Cold 0 0 1 (1.2%) 0.40  
       
Venous Access 12/62
a
 (19%) 14/82 (17.1%) 0.72  
Restart PIV  5 (6.4%) 8 (9.7%) 0.48  
CVC line reversal 2 (3.2%) 1 (1.2%) 0.40  
CVC positional 1 (1.6%) 1 (1.2%) 0.84  
CVC recirculation 0 0 1 (1.2%) 0.85  
Occluded CVC
g
 2 (3.2%) 2 (2.4%) 0.78  
PIV draw, CVC return 1 (1.6%) 2 (2.4%) 0.73  
Pain  3 (4.8%) 2 (2.4%) 0.44  
Bleeding 2 (3.2%) 1 (1.2%) 0.10  
Tape allergy 0 0 2 (2.4%) 0.22  
Infection 0 0 1 (1.2%) 0.38  
Cancelled/terminated 2 (3.2%) 0 0 0.10  
       
Technical  7/62
a
 (11.2%) 11/82 (13.4%) 0.70  
Multiple alarms 4 (6.4%) 7 (8.5%) 0.64  
Slow inlet 5 (8.1%) 6 (7.3%) 0.87  
Unstable interface 3 (4.8%) 2 (2.4%) 0.42   
Machine malfunction 0 0 2 (2.4%) 0.22  
Clotted circuit 1 (1.6%) 1 (1.4%) 0.73  
Blood loss
h
 1 (1.6%) 0 0 0.25  
Prolonged procedure 5 (8.1%) 6 (7.3%) 0.88  
Short procedure  3 (4.8%) 3 (3.6%) 0.63  
CVC-related
i
 6/7 (85.7%) 2/11 (16.7%) 0.006 OR=27 (2 - 468) 
       
Total Patients
j
 24/62 (38.7%) 39/82 (47.6%) 0.29  
Total Procedures
k
 28/110 (25.4%) 54/210 (25.7%) 0.96  
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a. Number of AE/No. patients. Note that some patients had more than one AE per 
procedure and the entire course of A-HPCC. As a result, the total number of AE 
exceeds the number of total number of patients in each category.  
b. % AE  
c. Odds ratio and 95% confidence interval 
d. AE in patients anticoagulated with heparin versus ACD-A. 
e. One adult patient with end stage renal disease, anticoagulated with 10% heparin 
in ACD-A at AC:WB ratio 1:22. 
f. Tetany, chest pain in two adult patients. 
g. CVC requiring multiple flushes and/or urokinase to access. 
h. Unable to return blood to patient 
i. No. and percent technical AE due to CVC malfunction. 
j. Total number of patients with at least one procedure-related AE 
k. Total number of procedures with at least one AE 
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Table 5. Review of Published Procedural AE during Pediatric HPC collection
a
  
 
       AE
a
 (% Patients / (% Procedures)) 
Study, 
year 
No. 
Pts 
No. 
Proc 
Donor 
Type 
Weight 
(in kg) 
RBC 
Prime 
Anti- 
coagulant
b
 
Citrate Venous 
Access 
Technical CV
c
 Other
d,e
 
            
Takaue [12],  
1995 
38 81 Auto < 20 Y ACD-A - - - 5.3 
(2.5) 
2.6
d
 
(1.2) 
            
Diaz [13], 
1996 
31 48 Auto 12 < 25 Y ACD-A 16.1
f 
(10.4) 
- - 6.4 
(4.2) 
3.2
e 
(2.1) 26 - 60 N 
            
Gorlin [2], 
1996 
14 85 Auto < 25 Y Heparin
g
 7.1
g
 
(1.2) 
64 
 
- 7.1
g
 
(1.2) 
- 
            
Madero 
[14], 1997 
56 71 Auto 9 < 25 Y ACD-A 23.2
h
 
(18.3
f 
) 
17.8
i
 12.5
i
 
(10
f 
) 
3.5 
(2.8) 
- 
25 - 62 N 
            
Pulsipher 
[8],2005 
201 218 Allo < 20 Y Heparin or 
ACD-A
j
 
10.1
j
 41
j 
 
- - - 
> 20 N 
            
Sevilla [4], 
2007 
12 13 Auto  7.5-10.9 Y Heparin
k
 16.7 
(15.3) 
- 8.3 
(7.7) 
91.7 
(85) 
- 
Allo 9 N
l
 
            
Michon [3], 
2007 
- 305 Auto, 
Allo 
< 15-20 Y
m
 ACD-A 24.9 
(11.8) 
- - 20.5 
(9.5) 
- 
> 20 N 
            
Sevilla [11], 
2008 
66 152 Allo < 20 N
l
 Heparin
k
  8 
(6.4
f
) 
7 
(6.4
f
) 
- 48 
(38.7) 
- 
> 20 N ACD-A 19.5 
(15
f
) 
- - 2.4 
(1.8) 
- 
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DeSilvestro 
[7], 2009 
210 291 Auto - - ACD-A 
(Heparin?)
n
 
4.3
f
 
(3.1) 
2
f
 
(1.4) 
5
f 
(3.8) 
0 - 
            
Fishmeister 
[15], 2000 
51 165 Auto 9 < 20 Y ACD-A 6.5
f
 
(21.2) 
39.2
f,o
 
(12.1) 
23.5
f,o
 
(18.8) 
5.9
f
 
(1.8) 
- 
20 - 30 N
l
 
30 - 92 N 
            
Orbach [16], 
2003 
24 48 Auto < 20 N
l
 ACD-A 20.8 
(10.4
f
) 
- 16.7 
(8.3
f
) 
20.8 
(10.4
f
) 
- 
            
Bolan [17], 
2004 
38 74 Auto, 
Allo 
11 - 29 Y Heparin, 
ACD-A
p
 
7.1
p 
(3.8) 
26.3
q
 
(13.5
f
) 
23.9
q
 
(12
f
) 
0 - 
            
Syczynsnski 
[10], 2012 
140 220 Allo 12 - 114 - ACD-A 
(Heparin?)
n
 
21 
 
15 
(9.5
f
) 
- 0.7 
(0.4) 
- 
            
Salazar-
Riojas [187], 
2014 
22 24 Auto, 
Allo 
< 20 Y Heparin
k
 0 0 - 4.5 
(4.2) 
- 
            
This study 6 6 Auto < 10 Y Heparin  0 0 0 0 0 
 30 40 Auto 11-20 Y ACD-A 17 13 10 0 3.8
d
 
 26 64 Auto > 20 Y/N ACD-A 35 27 15 0 0 
            
Total 62 110  8-103   25 
(14) 
19 
(12) 
11.3 
(7.3) 
0 1.8
d
 
(0.9) 
Abbreviations: -, not reported or available; ACD-A, acid citrate dextrose; Auto, autologous donor; Allo, allogeneic donor; Pt, patient; 
Proc, procedure; RBC prime, Y=RBC used in priming circuit, N=no RBC used for circuit priming.  
 
a. AE were classified as described in Table 1. The adjusted AE rate (% patients, % procedures) was determined for citrate, venous 
access, technical, cardiovascular, and “other” AE.   
b. Anticoagulant used during HPCC. 
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c. Cardiovascular symptoms, defined as hypotension, tachycardia and/or hemodynamic instability. 
d. Allergic transfusion reactions to RBC prime. 
e. Hypothermia. 
f. Estimated incidence based on number of patients and procedures. 
g. Low dose ACD-A (AC:WB ratio=1:25-1:30) and systemic heparinization. Hypotension, emesis and diaphoresis in one infant 
attributed to citrate. No problems with subsequent procedures using only systemic heparin and no ACD-A.  
h. Citrate AE includes documented hypocalcemia, parasthesias, nausea and vomiting. 
i. Venous AE includes nonfunctioning catheter requiring replacement, urokinase treatment and malfunctioning CVC requiring extreme 
positional maneuvers. Seven venous AE were associated with slow inlet rates. 
j. Multi-institutional survey of 22 pediatric collection centers. ACD-A discussed as primary anticoagulant for most donors (83% > 7 
years of age). Hypocalcemia or symptoms documented in 19/188 donors. Venous AE limited to catheter pain and bleeding in 44/106 
patients with CVC. 
k. Heparin (10 Units/mL) in ACD-A, administered at AC:WB ratios 1:20-1:30. 
l. Circuit primed with albumin.  
m. RBC prime if < 15 kg or if severely anemic.  
n. Multi-institutional registry study. No details regarding anticoagulation in younger patients.  
o. 31 technical AE, 19 due to flow-related issues and 12 due to instrumentation or software problems. Data reported as AE per 
procedure. 
p. Three anticoagulation protocols over 9 year period including systemic heparinization, systemic heparinization with low dose citrate 
(AC:WB ratio 1:20-1:30) and standard ACD-A (AC:WB ratio=1:10-1:13). Citrate AE rates calculated for patients anticoagulated 
with ACD-A (n=53) 
q. One patient had persistent bleeding and hematoma with a femoral catheter. Documented flow problems in 9/38 patients with CVC.  
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Figure Legends 
 
Figure 1.  AE rate in pediatric A-HPC patients. A) The percentage of patients with at 
least one AE by patient weight. B) The number of HPC procedures by patient weight 
(mean ± SD). Patients greater than 20 kg required significantly more HPC procedures 
than children less than 20 kg (p=0.003).  
 
Figure 2. Citrate AE. A) Distribution of gastrointestinal (black) and neurologic (white) 
citrate AE by patient age. B) Frequency of citrate AE by patient weight. Note that 
patients < 10 kg were anticoagulated with heparin.  C) Frequency of citrate AE by 
procedure day.  
 
Figure 3.  Impact of AE on CD34 collection rate: A) All AE, B) Citrate AE, C) Venous 
Access, and D) Technical AE. Legend, • procedures with AE, - -ο- - procedures 
with no AE.  
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Figure 3 
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